Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on August 19, 2009
Japanese Journal of Clinical Oncology 2009 39(12):829-832; doi:10.1093/jjco/hyp096
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/12/829    most recent
hyp096v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang, P.-h.
Right arrow Articles by Tsai, C.-c.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, P.-h.
Right arrow Articles by Tsai, C.-c.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Estrogen Replacement in Female Lung Cancer During Gefitinib Therapy

Ping-huai Wang1, Hao-chien Wang2 and Chien-chen Tsai3

1 Department of Internal Medicine, Far Eastern Memorial Hospital
2 Department of Internal Medicine, National Taiwan University Hospital
3 Department of Pathology, Far Eastern Memorial Hospital, Taipei, Taiwan

For reprints and all correspondence: Hao-chien Wang, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan. E-mail: haochienwang{at}gmail.com

Received May 12, 2009; accepted July 8, 2009

Estrogen receptor (ER) has been detected in some specimens of lung cancer. Estrogen has an effect on the growth of lung cancer cell lines. An inverse relationship between ER and epithelial growth factor receptor (EGFR) was reported in pre-clinical data. A 70-year-old female with lung adenocarcinoma, who achieved a partial response by gefitinib, underwent estrogen replacement for menopause-associated symptoms during gefinitib therapy. Lung nodules enlarged with 1-month estrogen use and regressed 6 weeks after the end of estrogen therapy. To our knowledge, this is the first case report regarding the interaction between estrogen and EGFR inhibitors.

Key Words: lung cancer • epidermal growth factor receptor • estrogen receptor • hormone replacement • gefitinib


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.